Monopar Therapeutics (NASDAQ:MNPR) Stock Price Down 5.7% – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR) traded down 5.7% on Monday. The company traded as low as $64.95 and last traded at $66.28. Approximately 218,899 shares changed hands during mid-day trading, an increase of 57% from the average daily volume of 139,654 shares. The stock had previously closed at $70.32.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a report on Thursday, July 23rd. HC Wainwright increased their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.00.

Monopar Therapeutics Price Performance

The stock’s 50 day simple moving average is $90.25 and its two-hundred day simple moving average is $77.38. The stock has a market capitalization of $444.74 million, a PE ratio of -30.54 and a beta of 1.50.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts predict that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares of the company’s stock, valued at $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the business’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the sale, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. The trade was a 22.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,688 shares of company stock worth $4,023,094 in the last ninety days. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new stake in Monopar Therapeutics in the 2nd quarter worth about $7,124,000. Siren L.L.C. lifted its holdings in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the last quarter. Bank of America Corp DE raised its position in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares during the period. ADAR1 Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in Monopar Therapeutics in the 1st quarter worth approximately $3,458,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.